/
PYPD
$4.97+$0.22 (+4.63%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$91.1M
19M shares
52-week range
$3.06 – $5.24
88% from low
Exchange
NASDAQ
CS
Borrow rate
9.48%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-266.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $411.0K | $947.0K | $1.0M | $1.1M | $1.7M | $0 | $0 | $0 |
| Gross profit | −$411.0K | −$947.0K | −$1.0M | −$1.1M | −$1.7M | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $12.6M | $14.1M | $17.0M | $30.4M | $28.0M | $16.1M | $22.8M | $23.8M |
| Operating income | −$18.4M | −$18.6M | −$26.3M | −$43.1M | −$38.9M | −$22.9M | −$28.0M | −$33.0M |
| EBITDA | −$42.1M | −$5.9M | −$35.9M | −$41.5M | −$36.4M | −$20.3M | −$25.8M | −$31.9M |
| Net income | $5.9M | −$6.9M | −$35.3M | −$40.7M | −$39.5M | −$23.9M | −$29.0M | −$34.2M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | 26.70 | 21.44 | -122.10 | -67.80 | -61.20 | -16.99 | -4.91 | -2.09 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $850000 | $-1.43 | $-1.75–$-1.11 | 3 |
| 2027 | $14M | $-1.25 | $-1.47–$-1.04 | 3 |
| 2028 | $81M | $0.10 | $0.01–$0.27 | 1 |
| 2029 | $162M | $1.74 | $0.25–$4.78 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.12
Price
$4.97
Implied downside
-97%
Peer comparison
PolyPid Ltd. Ordinary Shares
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
www.polypid.com- Employees
- 75
- IPO / List date
- Jun 26, 2020
Held by traders on TradeandTell
No one on the platform currently holds PYPD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PYPD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-21 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded PYPD yet.
